Ahmed Implant for Glaucoma: Procedure and Outcomes

The Ahmed glaucoma valve is a small silicone drainage device surgically implanted in the eye to lower intraocular pressure (IOP) when medications and standard surgeries have failed. In studies of patients with refractory glaucoma, the valve typically cuts eye pressure from the mid-30s down to the mid-teens within the first week, and that reduction holds for years in the majority of cases. The device stands out among glaucoma drainage implants because it contains a built-in valve mechanism that regulates flow from the moment it is placed, which lowers the risk of dangerously low pressure right after surgery. But the procedure comes with its own set of trade-offs, complications, and long-term considerations worth understanding before going in.

How the Device Works

The Ahmed valve is a thin silicone plate, roughly the size of a fingernail, with a small tube that channels fluid (aqueous humor) from inside the eye to a reservoir beneath the conjunctiva, the clear tissue covering the white of the eye. The plate sits against the outer wall of the eye, tucked under the eyelid where you cannot see or feel it. What makes it different from non-valved implants is a pair of thin membranes inside the body of the device that open and close in response to pressure. When pressure inside the eye rises above a set threshold, the membranes flex open and allow fluid to drain. When pressure drops back to a safe range, the membranes close again.

This self-regulating behavior has been confirmed in laboratory testing. Under both changing and steady flow conditions, the Ahmed device functioned as a true valve, increasing or decreasing resistance to keep pressure within a desired range.

¹ The practical benefit is that the surgeon does not need to completely obstruct the tube at the time of surgery, unlike non-valved devices that require a temporary ligature or stent to prevent over-drainage in the early days. The valve handles that job on its own.²

Who Is a Candidate

The Ahmed valve is generally reserved for eyes where first-line treatments have not worked or are unlikely to succeed. That includes people whose glaucoma has not responded to maximum medication, those who have had a failed trabeculectomy (the most common glaucoma surgery), and those with types of glaucoma that tend to scar aggressively after filtering surgery. Specific diagnoses where the device is frequently used include neovascular glaucoma (caused by abnormal blood vessel growth, often from diabetes or retinal vein occlusion), uveitic glaucoma (driven by chronic inflammation inside the eye), and various childhood glaucomas that resist conventional surgery.

The device is also a practical choice when a patient needs cataract removal at the same time as glaucoma surgery. Combined procedures pairing Ahmed valve implantation with cataract extraction have shown good results for both pressure control and visual improvement in eyes with conditions like iridocorneal endothelial syndrome.³ That said, the valve is not usually the first surgery offered to a patient with newly diagnosed open-angle glaucoma who has never tried other interventions. It fills a specific role in the surgical ladder.

The Surgical Procedure

The operation is performed under local or general anesthesia and takes roughly 45 minutes to an hour. The surgeon makes a small opening in the conjunctiva, usually in the upper outer quadrant of the eye, and secures the plate to the sclera (the white outer shell) with sutures. The tube is then trimmed to the correct length and inserted into the anterior chamber of the eye through a tiny needle-made track near the edge of the cornea. Correct tube length matters: too long and it can touch the iris or lens, too short and it may retract.

Because the tube sits just beneath the conjunctiva, it needs to be covered with a patch graft to prevent the thin tissue from wearing through over time. Common graft materials include preserved donor sclera, pericardium (the tissue sac around the heart), and processed corneal tissue.⁴ Each has trade-offs in cost, availability, and how well it holds up over the years.⁵ A sutureless variant using fibrin glue instead of stitches to hold the graft in place has been described, and some surgeons use a “short tunnel small flap” technique that avoids a separate graft altogether.⁶ At the end of the procedure, the conjunctiva is sutured closed, and the surgeon often gives a local injection of steroid and antibiotic. The patient goes home the same day and starts a regimen of anti-inflammatory and antibiotic eye drops.

What to Expect in the First Few Months

Eye pressure usually drops sharply in the first week. In one large series that tracked patients with refractory glaucoma, average pressure fell from about 36 mmHg before surgery to roughly 13 mmHg at one week.⁷ Vision, on the other hand, typically dips for the first week or so. One study found that average visual acuity was roughly one Snellen line worse at one week compared with the preoperative level, then gradually climbed back to baseline by three months and stayed there through six months.⁸ Patients should expect some blurriness and mild discomfort during this recovery window.

The most characteristic early challenge is the hypertensive phase, a temporary spike in eye pressure that typically occurs within the first one to three months after surgery. The body forms a capsule of scar tissue around the plate on the outside of the eye, and during this remodeling process the drainage can slow down enough that pressure climbs back up. In one series, about a fifth of eyes experienced a hypertensive phase.⁹ It is usually managed with temporary glaucoma medications or in-office procedures, and in most cases the pressure settles back down as the capsule matures and becomes more permeable to fluid. Surgeons sometimes use anti-scarring agents or steroid regimens to limit this spike, though there is no consensus on the best prevention strategy.

Long-Term Pressure Control and Success Rates

Over the long haul, the Ahmed valve reliably holds pressure in the mid-teens for most patients, though a gradual drift upward is common and some patients eventually need additional glaucoma drops or a second surgery. In a study of 135 eyes with various types of refractory glaucoma followed for up to five years, average pressure at the five-year mark was about 16 mmHg, down from a pre-surgery average of 36 mmHg. The cumulative probability of surgical success (meaning adequate pressure control without needing another glaucoma operation) was roughly 73% at one year and 64% at both three and five years.⁷ A Scottish cohort showed similar numbers: average pressure dropped from about 32 mmHg to 14 mmHg at five years, with a five-year success rate of 65% and a reoperation rate of 37%.¹⁰

A useful way to think about these numbers: about two in three patients will still have good pressure control from the valve at five years, but the majority will need at least one or two glaucoma drops to maintain it. The average number of medications drops substantially right after surgery (from about four to nearly zero in the first weeks) but creeps back up to one or two over the following years.⁷ That is still a meaningful reduction from the three or four medications many of these patients were using before surgery, but it is worth setting realistic expectations: the valve rarely eliminates the need for drops entirely over time.

Complications to Know About

The complication profile of the Ahmed valve has been studied extensively. Roughly half of eyes in large series experience at least one complication, though many are minor and resolve on their own.⁷ The most commonly reported issues fall into a few categories:

Hypertensive phase: Temporary pressure elevation in the first months, as described above, occurring in roughly one in five patients.
Hyphema: Bleeding inside the front of the eye, seen in about 6% of cases in one series and up to 15% in neovascular glaucoma eyes, where abnormal blood vessels are part of the disease.⁹¹¹
Hypotony: Excessively low pressure, which can cause fluid to collect behind the retina. The Ahmed valve’s built-in flow regulation makes true hypotony uncommon, at under 2% in most series.
Tube erosion: Over months or years, the conjunctiva and patch graft covering the tube can thin and break down, exposing the tube to the outside world. This is a serious late complication because it opens a direct path for infection into the eye. When erosion occurs, the tube needs to be re-covered with new graft tissue, but recurrence is common: in one surgical series, three out of five patients who had their tubes re-covered experienced erosion again, and two ultimately required device removal.¹²
Encapsulated bleb: A thick wall of scar tissue can form around the plate, blocking drainage and sending pressure back up. This is the main driver of long-term failure and sometimes requires a revision procedure called excisional bleb revision with capsulectomy, where the surgeon opens up the scar and applies an anti-scarring drug.¹³

Corneal Health Over Time

One concern that does not always come up in the initial conversation about surgery is the effect on the cornea. The inner layer of the cornea, the endothelium, is a single-cell-thick sheet that keeps the cornea clear by pumping fluid out of it. These cells do not regenerate. After Ahmed valve implantation, the rate of endothelial cell loss in the operated eye is roughly seven percent per year, compared with virtually no loss in the fellow eye.¹⁴ Over five years, the cumulative risk of the cornea failing altogether (becoming permanently hazy) is around 3%. That sounds low, but it is not zero, and in eyes where the tube sits in the front chamber rather than behind the iris, the cell loss is roughly twice as fast.¹⁵ For patients who already have a low endothelial cell count from prior surgeries or other conditions, this ongoing attrition is something to discuss with the surgeon, because a corneal transplant may eventually become necessary.

How It Compares with the Baerveldt Implant

The Baerveldt implant is the Ahmed’s main competitor among glaucoma drainage devices. It is larger (more surface area for drainage) and does not contain a valve, so the tube must be temporarily tied off or stented at surgery to prevent over-drainage in the early postoperative period. Two large multicenter trials compared the two devices head to head, and their pooled five-year data tell a fairly clear story. The Baerveldt group achieved lower average pressure (about 13 mmHg versus 16 mmHg) on fewer medications, and had a lower cumulative failure rate (37% versus 49%).¹⁶ The Baerveldt group also needed fewer additional glaucoma surgeries (8% versus 16%).

But the Baerveldt was not universally better. It carried a meaningfully higher risk of hypotony-related failure, at about 4.5% compared with under 1% for the Ahmed.¹⁶ Hypotony after a Baerveldt can mean a flat anterior chamber, choroidal detachment, and occasionally permanent vision loss. Overall complication and intervention rates were similar between the two devices.¹⁷ So the choice often comes down to the clinical scenario: the Ahmed’s built-in valve makes it safer when hypotony would be especially dangerous (for instance, in eyes that already have very thin corneas or compromised retinas), while the Baerveldt’s lower long-term failure rate may matter more in younger patients who need decades of pressure control.

Ahmed Valve Versus Trabeculectomy

Trabeculectomy, the traditional filtering surgery, creates a new drainage pathway by cutting a small flap in the sclera and letting fluid seep out under the conjunctiva. In straightforward open-angle glaucoma, trabeculectomy remains the gold-standard first surgery. But in complicated eyes, the comparison narrows. A study in neovascular glaucoma found one-year success rates of 70% for the Ahmed valve and 65% for trabeculectomy, with no significant difference over two years.¹⁸ In eyes that had previously undergone vitrectomy (surgery inside the back of the eye), overall success was also comparable between the two, though trabeculectomy achieved a higher rate of complete success without any drops: 40% of trabeculectomy eyes were medication-free at last follow-up compared with 15% of Ahmed eyes.¹⁹

In other words, trabeculectomy tends to deliver lower ultimate pressure and a better chance of being completely drop-free, but the Ahmed valve offers more predictable early pressure control and avoids some of the catastrophic early complications (like a flat chamber or bleb leak) that can follow trabeculectomy in high-risk eyes. The decision often hinges on how much surgical scarring the eye has already endured and how tolerant the eye is likely to be of a filtering bleb.

Outcomes in Neovascular Glaucoma

Neovascular glaucoma is among the most difficult forms of the disease to treat. Abnormal blood vessels grow across the drainage angle of the eye, choking off outflow and driving pressure dangerously high. The Ahmed valve can bring immediate relief, but the long-term numbers are sobering. One study found a one-year success rate of about 67%, with average pressure dropping from the high 40s to the low 20s.¹¹ However, success rates decay more steeply than in other forms of glaucoma. An American Ophthalmological Society thesis reported that five-year success fell to about 21% in neovascular eyes compared with 82% in a control group with other glaucoma types.²⁰ A separate study comparing Ahmed and Baerveldt devices specifically in neovascular glaucoma found that the Baerveldt had a significantly higher success rate, though postoperative complication rates were similar between the two.²¹ Hyphema was the most common postoperative issue, affecting about 15% of neovascular eyes, and prior panretinal photocoagulation appeared to improve outcomes.

Pediatric and Uveitic Glaucoma

The Ahmed valve is one of the few surgical options widely used in children with refractory glaucoma, partly because its flow-restricting valve reduces the risk of the severe hypotony that a child’s soft, growing eye is especially vulnerable to. A review of the pediatric literature found that adequate pressure control can be achieved and sustained for five or more years. However, most children eventually need additional glaucoma drops, and younger patients face unique complications including pupil distortion and cataract formation, particularly when the valve is placed during the first year of life as the eye is still growing.²² One study found that at one year, success was around 90% regardless of age group, but by five years it had dropped to roughly 53% in children under three compared with 72% in older children.²³

In uveitic glaucoma, where chronic inflammation inside the eye drives both the glaucoma and an aggressive scarring response, the Ahmed valve has shown good short-term results. One series reported a 94% success rate at one year with an average pressure reduction of nearly 24 mmHg, though the authors credited aggressive control of the underlying uveitis with immunosuppressive therapy as a key contributor.²⁴ Longer follow-up is less rosy: another study found that success fell to about 50% at four years, and three-quarters of patients still needed glaucoma medications.²⁵ A novel approach pairs the Ahmed valve with a tiny sustained-release steroid implant (fluocinolone acetonide) placed at the time of surgery, which in one series led to similar pressure control but fewer glaucoma drops and better inflammation control at one year.²⁶

Silicone Versus Polypropylene Models

The Ahmed valve has gone through significant material changes. Earlier models used a rigid polypropylene plate, while the current standard model (the FP7) uses a more flexible silicone plate. This is not a trivial distinction. Head-to-head comparisons found that the silicone version achieved better pressure reduction and had a lower rate of failure due to uncontrolled high pressure (about 4% with silicone versus 20% with polypropylene).²⁷ The prevailing theory is that the softer silicone triggers less of an inflammatory and fibrotic response from the surrounding tissue, leading to a thinner and more permeable capsule. The trade-off: the silicone model had a somewhat higher rate of non-tube-related serious complications in one study, though overall the silicone design is now considered the preferred version.²⁸ If you are reading older studies, it is worth checking which model was used, because outcomes from the polypropylene era may not reflect what the current device can do.

When the Valve Fails and What Comes Next

Failure usually means the eye pressure has crept back up despite the implant, most often because thick scar tissue has walled off the plate. The first-line rescue is often bleb revision: the surgeon reopens the area around the plate, peels away the scar capsule, applies an anti-scarring agent like mitomycin C, and closes things back up. Short-term results of this procedure are encouraging, with one series reporting a 93% success rate at six months and a meaningful drop in both pressure and medication use.¹³ But the long-term durability of revisions is less certain, and some eyes eventually need the device removed entirely, followed by a different surgical approach. In one case report, a severely encapsulated valve with fibrous tissue growing into the valve mechanism itself required removal and conversion to trabeculectomy after multiple failed revision attempts.²⁹

The Scottish cohort data give a practical sense of scale: at five years, 37% of patients had undergone at least one reoperation (not counting cataract surgery).¹⁰ That is a substantial fraction, and it underscores the reality that an Ahmed valve is not a set-it-and-forget-it solution. Lifelong monitoring, ongoing medication adjustments, and the possibility of further procedures are part of the package. For many patients with refractory glaucoma, though, the alternative is worse: uncontrolled pressure and progressive, irreversible vision loss. In that context, a device that keeps pressure controlled in two out of three eyes at five years, even with medications and the occasional tune-up, represents a meaningful intervention.

1
Ophthalmology. Characteristics of glaucoma drainage implants during dynamic and steady-state flow conditions
2
PubMed Central. Control and optimisation of fluid flow in glaucoma drainage device surgery
3
PubMed Central. Long-term surgical outcomes of combined Ahmed glaucoma valve implantation and phacoemulsification with intraocular lens implantation for patients with glaucoma secondary to iridocorneal endothelial syndrome
4
PubMed Central. Ahmed glaucoma valve implant: surgical technique and complications
5
Asia-Pacific Journal of Ophthalmology. Grafts in Glaucoma Surgery: A Review of the Literature
6
PubMed. Ahmed Glaucoma Valve Implantation: Graft-Free Short Tunnel Small Flap versus Scleral Patch Graft after 1-Year Follow-up: A Randomized Clinical Trial
7
PubMed Central. Long-term surgical outcomes of Ahmed valve implantation in refractory glaucoma according to the type of glaucoma
8
PubMed Central. Short-term postoperative visual acuity decrease and recovery after Ahmed tube shunt procedure for glaucoma
9
PubMed Central. Safety and Efficacy of Ahmed Valve on Intractable Glaucoma in Saudi Population
10
PubMed Central. Long-Term Outcomes of Ahmed Glaucoma Valve Surgery in a Scottish Cohort of Patients With Refractory Glaucoma
11
International Journal of Medical Sciences. Efficacy of Ahmed Glaucoma Valve Implantation on Neovascular Glaucoma
12
Scientific Reports. Tube erosions following glaucoma drainage device implantations
13
PubMed Central. Short-term outcomes of mitomycin C-augmented excisional bleb revision with capsulectomy for failed Ahmed glaucoma valve
14
PubMed. Changes in corneal endothelial cell density and the cumulative risk of corneal decompensation after Ahmed glaucoma valve implantation
15
PubMed Central. The Effect of Tube Location on Corneal Endothelial Cells in Patients with Ahmed Glaucoma Valve
16
PubMed. Five-Year Pooled Data Analysis of the Ahmed Baerveldt Comparison Study and the Ahmed Versus Baerveldt Study
17
PubMed. The Ahmed Versus Baerveldt Study: Five-Year Treatment Outcomes
18
PubMed Central. Trabeculectomy versus Ahmed Glaucoma Valve implantation in neovascular glaucoma
19
PubMed Central. Long-term Outcomes of Trabeculectomy Versus Ahmed Glaucoma Valve Implantation in Vitrectomized Eyes
20
PubMed Central. The Ahmed glaucoma valve in neovascular glaucoma (An AOS Thesis)
21
PubMed Central. Surgical Outcomes of Baerveldt Glaucoma Implant Versus Ahmed Glaucoma Valve in Neovascular Glaucoma: A Retrospective Multicenter Study
22
PubMed Central. Ahmed glaucoma valve in children: A review
23
PubMed. Clinical outcomes of Ahmed glaucoma valve implantation in pediatric glaucoma
24
PubMed. Management of uveitic glaucoma with Ahmed glaucoma valve implantation
25
PubMed. Long-term results of Ahmed glaucoma valve implantation for uveitic glaucoma
26
PubMed Central. A retrospective study on the outcomes of Ahmed valve versus Ahmed valve combined with fluocinolone implant in uveitic glaucoma
27
PubMed. Comparison of safety and efficacy between silicone and polypropylene Ahmed glaucoma valves in refractory glaucoma
28
PubMed. Comparison of polypropylene and silicone Ahmed Glaucoma Valves
29
Annals of Optometry and Contact Lens. Encapsulated Bleb and Fibrous Ingrowth in the Ahmed Glaucoma Valve System and Bleb Revision with Mitomycin-C